Antonio Nicolucci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5238607/publications.pdf

Version: 2024-02-01

75 papers 3,316 citations

201385 27 h-index 55 g-index

79 all docs

79 docs citations

79 times ranked 4895 citing authors

#	Article	IF	CITATIONS
1	Is it time to consider depression as a major complication of type 2 diabetes? Evidence from a large population-based cohort study. Acta Diabetologica, 2022, 59, 95-104.	1.2	9
2	Effect of a Behavioural Intervention for Adoption and Maintenance of a Physically Active Lifestyle on Psychological Well-Being and Quality of Life in Patients with Type 2 Diabetes: The IDES_2 Randomized Clinical Trial. Sports Medicine, 2022, 52, 643-654.	3.1	5
3	Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: Results from the longitudinal global discover study. American Heart Journal, 2022, 243, 232-239.	1.2	14
4	Accuracy of the Standard GlucoNavii Mentor in Blood Glucose Monitoring According to International Organization for Standardization 15197:2013 Criteria. JMIR Diabetes, 2022, 7, e20774.	0.9	0
5	The adolescent with obesity: what perspectives for treatment?. Italian Journal of Pediatrics, 2022, 48, 9.	1.0	29
6	Quality of life in people with type 2 diabetes in the 3Âyears following initiation of second-line therapy: The DISCOVER study. Diabetes Research and Clinical Practice, 2022, 185, 109218.	1.1	4
7	Compatibility of PiC Insupen Needles with a Broad Range of Pens for the Injection of Subcutaneously Administered Drugs for Diabetes. Medical Devices: Evidence and Research, 2022, Volume 15, 71-77.	0.4	o
8	Socioeconomic Factors Associated With Glycemic Measurement and Poor HbA1c Control in People With Type 2 Diabetes: The Global DISCOVER Study. Frontiers in Endocrinology, 2022, 13, 831676.	1.5	7
9	Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global <scp>DISCOVER</scp> study. Diabetes, Obesity and Metabolism, 2022, 24, 1734-1740.	2.2	О
10	Comparative effectiveness of Glargine 300 U/mL vs. Degludec 100 U/mL in patients with type 2 diabetes switching from $1\hat{A}^{\circ}$ generation basal insulins. Nutrition, Metabolism and Cardiovascular Diseases, 2022, , .	1.1	1
11	Independent association of atherogenic dyslipidaemia with all ause mortality in individuals with type 2 diabetes and modifying effect of gender: a prospective cohort study. Cardiovascular Diabetology, 2021, 20, 28.	2.7	6
12	Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ, The, 2021, 372, m4573.	3.0	322
13	Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study. Cardiovascular Diabetology, 2021, 20, 59.	2.7	23
14	Lower risk of death and cardiovascular events in patients with diabetes initiating glucagonâ€like peptideâ€1 receptor agonists or sodiumâ€glucose cotransporterâ€2 inhibitors: A realâ€world study in two Italian cohorts. Diabetes, Obesity and Metabolism, 2021, 23, 1484-1495.	2.2	20
15	Associations between secondâ€line glucoseâ€lowering combination therapies with metformin and <scp>HbA1c</scp> , body weight, quality of life, hypoglycaemic events and glucoseâ€lowering treatment intensification: The <scp>DISCOVER</scp> study. Diabetes, Obesity and Metabolism, 2021, 23, 1823-1833.	2.2	7
16	Glycated Albumin for Glycemic Control in T2DM Population: A Multi-Dimensional Evaluation. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 453-464.	0.7	2
17	Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study. BMJ Open Diabetes Research and Care, 2021, 9, e001585.	1.2	4
18	Prevalence and progression of chronic kidney disease among patients with type <scp>2</scp> diabetes: Insights from the <scp>DISCOVER</scp> study. Diabetes, Obesity and Metabolism, 2021, 23, 1956-1960.	2.2	8

#	Article	IF	CITATIONS
19	Early versus late intensification of glucose-lowering therapy in patients with type 2 diabetes: Results from the DISCOVER study. Diabetes Research and Clinical Practice, 2021, 178, 108947.	1.1	3
20	Effects of weight loss medications on mortality and cardiovascular events: A systematic review of randomized controlled trials in adults with overweight and obesity. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2587-2595.	1.1	7
21	Perceived Benefits, Barriers, and Facilitators of a Digital Patient-Reported Outcomes Tool for Routine Diabetes Care: Protocol for a National, Multicenter, Mixed Methods Implementation Study. JMIR Research Protocols, 2021, 10, e28391.	0.5	4
22	Effectiveness of Ascophyllum nodosum and Fucus vesiculosus on Metabolic Syndrome Components: A Real-World, Observational Study. Journal of Diabetes Research, 2021, 2021, 1-8.	1.0	6
23	Health-related quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: The DISCOVER study. Diabetes Research and Clinical Practice, 2021, 180, 108974.	1.1	3
24	Comparative Effectiveness of Switching From First-Generation Basal Insulin to GlargineÂ300ÂU/ml or DegludecÂ100ÂU/ml in TypeÂ1 Diabetes: The RESTORE-1 Study. Diabetes Therapy, 2021, 12, 509-525.	1.2	11
25	Temporal trends in intensification of glucose-lowering therapy for type 2 diabetes in Italy: Data from the AMD Annals initiative and their impact on clinical inertia. Diabetes Research and Clinical Practice, 2021, 181, 109096.	1.1	6
26	Design and rationale of DISCOVER global registry in type 2 diabetes: Real-world insights of treatment patterns and its relationship with cardiovascular, renal, and metabolic multimorbidities. Journal of Diabetes and Its Complications, 2021, 35, 108077.	1.2	3
27	Clinical profiles and quality of care of adults with type 1 diabetes according to their cardiovascular Risk: A Multicenter, Observational, retrospective study. Diabetes Research and Clinical Practice, 2021, 182, 109131.	1.1	3
28	Glycaemic control in patients with type 2 diabetes initiating secondâ€line therapy: Results from the global DISCOVER study programme. Diabetes, Obesity and Metabolism, 2020, 22, 66-78.	2.2	20
29	Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes. Diabetes Therapy, 2020, 11, 573-584.	1.2	25
30	Renal hyperfiltration is independently associated with increased all-cause mortality in individuals with type 2 diabetes: a prospective cohort study. BMJ Open Diabetes Research and Care, 2020, 8, e001481.	1.2	22
31	Clinical Outcomes of Switching to Insulin Glargine 300 U/ml from Other Basal Insulins in People with Type 2 Diabetes in Italy: A Real-World Study. Diabetes Therapy, 2020, 11, 2283-2298.	1.2	3
32	Association between On-Treatment Haemoglobin A1c and All-Cause Mortality in Individuals with Type 2 Diabetes: Importance of Personalized Goals and Type of Anti-Hyperglycaemic Treatment. Journal of Clinical Medicine, 2020, 9, 246.	1.0	2
33	Switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin: effect on quality of life after liver transplantation. Health and Quality of Life Outcomes, 2020, 18, 99.	1.0	3
34	Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice. Advances in Therapy, 2019, 36, 2895-2909.	1.3	11
35	Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a secondâ€line therapy: Results from the global DISCOVER study programme. Diabetes, Obesity and Metabolism, 2019, 21, 2474-2485.	2.2	36
36	Penetration force and cannula sliding profiles of different pen needles: the PICASSO study. Medical Devices: Evidence and Research, 2019, Volume 12, 311-317.	0.4	8

#	Article	IF	CITATIONS
37	Incidence of severe hypoglycemia and possible associated factors in pediatric patients with type 1 diabetes mellitus in the realâ€life, postâ€DCCT setting: a systematic review. Pediatric Diabetes, 2019, 20, 678-692.	1.2	7
38	Effect of a Behavioral Intervention Strategy on Sustained Change in Physical Activity and Sedentary Behavior in Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2019, 321, 880.	3.8	89
39	Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study. Diabetes Research and Clinical Practice, 2019, 151, 20-32.	1.1	63
40	Overall Quality of Care Predicts the Variability of Key Risk Factors for Complications in Type 2 Diabetes: An Observational, Longitudinal Retrospective Study. Diabetes Care, 2019, 42, 514-519.	4.3	28
41	Urban diabetes: the case of the metropolitan area of Rome. Acta Biomedica, 2019, 90, 209-214.	0.2	7
42	Haemoglobin A1c variability is a strong, independent predictor of all ause mortality in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 1885-1893.	2.2	45
43	Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study. Advances in Therapy, 2018, 35, 243-253.	1.3	19
44	Cost-effectiveness of sensor-augmented pump therapy in two different patient populations with type 1 diabetes in Italy. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 707-715.	1.1	11
45	Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating secondâ€line therapy after metformin monotherapy: <scp>R</scp> etrospective data for 10 256 individuals from the <scp>U</scp> nited <scp>K</scp> ingdom and <scp>G</scp> ermany. Diabetes, Obesity and Metabolism, 2018, 20, 389-399.	2.2	38
46	Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovascular Diabetology, 2018, 17, 150.	2.7	149
47	Obesity in Germany and Italy: prevalence, comorbidities, and associations with patient outcomes. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 457-475.	0.7	17
48	Efficacy, safety and acceptability of the new pen needle 34G × 3.5 mm: a crossover randomized non-inferiority trial; AGO 02 study. Current Medical Research and Opinion, 2018, 34, 1699-1704.	0.9	3
49	Real-world use of self-monitoring of blood glucose in people with type 2 diabetes: an urgent need for improvement. Acta Diabetologica, 2018, 55, 1059-1066.	1.2	16
50	A multistep approach for the stratification of the risk of severe hypoglycemia in patients with type 2 diabetes. Minerva Endocrinology, 2018, 43, 501-510.	0.6	7
51	Variability in <scp>HbA1c</scp> , blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 1570-1578.	2.2	70
52	Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program. Journal of Diabetes and Its Complications, 2017, 31, 1188-1196.	1.2	46
53	Effect of a Behavioral Intervention Strategy for Adoption and Maintenance of a Physically Active Lifestyle: The Italian Diabetes and Exercise Study 2 (IDES_2). Diabetes Care, 2017, 40, 1444-1452.	4.3	26
54	Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A metaâ€analysis from the ⟨scp⟩GetGoal⟨/scp⟩ programme. Diabetes, Obesity and Metabolism, 2017, 19, 248-256.	2.2	6

#	Article	IF	Citations
55	Level and correlates of physical activity and sedentary behavior in patients with type 2 diabetes: A cross-sectional analysis of the Italian Diabetes and Exercise Study_2. PLoS ONE, 2017, 12, e0173337.	1.1	29
56	Mobile App-Based Interventions to Support Diabetes Self-Management: A Systematic Review of Randomized Controlled Trials to Identify Functions Associated with Glycemic Efficacy. JMIR MHealth and UHealth, 2017, 5, e35.	1.8	220
57	The Drug Derived Complexity Index (DDCI) Predicts Mortality, Unplanned Hospitalization and Hospital Readmissions at the Population Level. PLoS ONE, 2016, 11, e0149203.	1.1	30
58	Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2016, 316, 313.	3.8	329
59	Gender-Disparities in Adults with Type 1 Diabetes: More Than a Quality of Care Issue. A Cross-Sectional Observational Study from the AMD Annals Initiative. PLoS ONE, 2016, 11, e0162960.	1.1	31
60	The Italian Diabetes and Exercise Study 2 (IDES-2): a long-term behavioral intervention for adoption and maintenance of a physically active lifestyle. Trials, 2015, 16, 569.	0.7	12
61	Trends over 8Âyears in quality of diabetes care: results of the AMD Annals continuous quality improvement initiative. Acta Diabetologica, 2015, 52, 557-571.	1.2	36
62	Interplay among patient empowerment and clinical and person-centered outcomes in type 2 diabetes. The BENCH-D study. Patient Education and Counseling, 2015, 98, 1142-1149.	1.0	43
63	HbA1c Variability as an Independent Correlate of Nephropathy, but Not Retinopathy, in Patients With Type 2 Diabetes. Diabetes Care, 2013, 36, 2301-2310.	4.3	130
64	Impact of the "Diabetes Interactive Diary―Telemedicine System on Metabolic Control, Risk of Hypoglycemia, and Quality of Life: A Randomized Clinical Trial in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2013, 15, 670-679.	2.4	80
65	Changes in Physical Fitness Predict Improvements in Modifiable Cardiovascular Risk Factors Independently of Body Weight Loss in Subjects With Type 2 Diabetes Participating in the Italian Diabetes and Exercise Study (IDES). Diabetes Care, 2012, 35, 1347-1354.	4.3	81
66	Development and validation of a questionnaire evaluating the impact of hepatitis B immune globulin prophylaxis on the quality of life of liver transplant recipients. Liver Transplantation, 2012, 18, 332-339.	1.3	17
67	Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. Journal of Hypertension, 2011, 29, 1802-1809.	0.3	198
68	Reproducibility of albuminuria in type 2 diabetic subjects. Findings from the Renal Insufficiency And Cardiovascular Events (RIACE) study. Nephrology Dialysis Transplantation, 2011, 26, 3950-3954.	0.4	65
69	Improvement of Quality of Life With Supervised Exercise Training in Subjects With Type 2 Diabetes Mellitus. Archives of Internal Medicine, 2011, 171, 1951.	4.3	28
70	Quality of Diabetes Care Predicts the Development of Cardiovascular Events: Results of the AMD-QUASAR Study. Diabetes Care, 2011, 34, 347-352.	4.3	53
71	Effect of an Intensive Exercise Intervention Strategy on Modifiable Cardiovascular Risk Factors in Subjects With Type 2 Diabetes Mellitus <subtitle>A Randomized Controlled Trial: The Italian Diabetes and Exercise Study (IDES)</subtitle> <alt-title>Intensive Exercise and Modifiable CV Risk Factors</alt-title> . Archives of Internal Medicine. 2010. 170. 1794.	4.3	270
72	Diabetes Interactive Diary: A New Telemedicine System Enabling Flexible Diet and Insulin Therapy While Improving Quality of Life. Diabetes Care, 2010, 33, 109-115.	4.3	142

Antonio Nicolucci

#	Article	IF	CITATIONS
73	Quality of diabetes care predicts the development of cardiovascular events: Results of the QuED study. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 57-65.	1.1	37
74	The Italian Diabetes and Exercise Study (IDES): Design and methods for a prospective Italian multicentre trial of intensive lifestyle intervention in people with type 2 diabetes and the metabolic syndrome. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 585-595.	1.1	50
75	Baseline Quality-of-Care Data From a Quality-Improvement Program Implemented by a Network of Diabetes Outpatient Clinics. Diabetes Care, 2008, 31, 2166-2168.	4.3	61